Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials / Logan SHURTZ in Autism, 27-4 (May 2023)  

Public ISBD [article]  inAutism > 27-4 (May 2023) . - p.952-966 Titre : Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials Type de document : Texte imprimé et/ou numérique Auteurs : Logan SHURTZ, Auteur ; Chloe SCHWARTZ, Auteur ; Charlotte DISTEFANO, Auteur ; James C MCPARTLAND, Auteur ; April R LEVIN, Auteur ; Geraldine DAWSON, Auteur ; Natalia M KLEINHANS, Auteur ; Susan FAJA, Auteur ; Sara J WEBB, Auteur ; Frederick SHIC, Auteur ; Adam J NAPLES, Auteur ; Helen SEOW, Auteur ; Raphael A BERNIER, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A SUGAR, Auteur ; James DZIURA, Auteur ; Damla SENTURK, Auteur ; Megha SANTHOSH, Auteur ; Shafali S JESTE, Auteur Article en page(s) : p.952-966 Langues : Anglais (eng) Mots-clés : aberrant behavior checklist,antipsychotics,autism spectrum disorders,clinical trials,medications,Vineland Adaptive Behavior Scales Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options.Lay abstractChildren with autism spectrum disorder are prescribed a variety of medications that affect the central nervous system (psychotropic medications) to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity of the sample and prevent contamination of biomarkers or clinical endpoints. However, this choice may significantly diminish the clinical representativeness of the sample. In a recent multisite study designed to identify biomarkers and behavioral endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, thus providing a unique opportunity to examine characteristics of psychotropic medication use in a research cohort and to guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the ABC-CT and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half of these children. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Descriptive analysis showed that children taking antipsychotics displayed a trend toward greater overall impairment. Our findings suggest that exclusion of children taking concomitant psychotropic medications in trials could limit the clinical representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. En ligne : https://doi.org/10.1177/13623613221121425 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=499 [article] Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials [Texte imprimé et/ou numérique] / Logan SHURTZ, Auteur ; Chloe SCHWARTZ, Auteur ; Charlotte DISTEFANO, Auteur ; James C MCPARTLAND, Auteur ; April R LEVIN, Auteur ; Geraldine DAWSON, Auteur ; Natalia M KLEINHANS, Auteur ; Susan FAJA, Auteur ; Sara J WEBB, Auteur ; Frederick SHIC, Auteur ; Adam J NAPLES, Auteur ; Helen SEOW, Auteur ; Raphael A BERNIER, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A SUGAR, Auteur ; James DZIURA, Auteur ; Damla SENTURK, Auteur ; Megha SANTHOSH, Auteur ; Shafali S JESTE, Auteur . - p.952-966. Langues : Anglais (eng) in Autism > 27-4 (May 2023) . - p.952-966 Mots-clés : aberrant behavior checklist,antipsychotics,autism spectrum disorders,clinical trials,medications,Vineland Adaptive Behavior Scales Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options.Lay abstractChildren with autism spectrum disorder are prescribed a variety of medications that affect the central nervous system (psychotropic medications) to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity of the sample and prevent contamination of biomarkers or clinical endpoints. However, this choice may significantly diminish the clinical representativeness of the sample. In a recent multisite study designed to identify biomarkers and behavioral endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, thus providing a unique opportunity to examine characteristics of psychotropic medication use in a research cohort and to guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the ABC-CT and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half of these children. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Descriptive analysis showed that children taking antipsychotics displayed a trend toward greater overall impairment. Our findings suggest that exclusion of children taking concomitant psychotropic medications in trials could limit the clinical representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. En ligne : https://doi.org/10.1177/13623613221121425 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=499

Frontal EEG alpha asymmetry in youth with autism: Sex differences and social-emotional correlates / Megha SANTHOSH ; Anna KRESSE ; Elizabeth AYLWARD ; Raphael BERNIER ; Susan BOOKHEIMER ; Shafali JESTE ; Allison JACK ; James C. MCPARTLAND ; Adam NAPLES ; John D. VAN HORN ; Kevin PELPHREY ; Sara Jane WEBB ; ACE GENDAAR NETWORK in Autism Research, 16-12 (December 2023)  

Public ISBD [article]  inAutism Research > 16-12 (December 2023) . - p.2364-2377 Titre : Frontal EEG alpha asymmetry in youth with autism: Sex differences and social-emotional correlates Type de document : Texte imprimé et/ou numérique Auteurs : Megha SANTHOSH, Auteur ; Anna KRESSE, Auteur ; Elizabeth AYLWARD, Auteur ; Raphael BERNIER, Auteur ; Susan BOOKHEIMER, Auteur ; Shafali JESTE, Auteur ; Allison JACK, Auteur ; James C. MCPARTLAND, Auteur ; Adam NAPLES, Auteur ; John D. VAN HORN, Auteur ; Kevin PELPHREY, Auteur ; Sara Jane WEBB, Auteur ; ACE GENDAAR NETWORK, Auteur Article en page(s) : p.2364-2377 Index. décimale : PER Périodiques Résumé : Abstract In youth broadly, EEG frontal alpha asymmetry (FAA) associates with affective style and vulnerability to psychopathology, with relatively stronger right activity predicting risk for internalizing and externalizing behaviors. In autistic youth, FAA has been related to ASD diagnostic features and to internalizing symptoms. Among our large, rigorously characterized, sex-balanced participant group, we attempted to replicate findings suggestive of altered FAA in youth with an ASD diagnosis, examining group differences and impact of sex assigned at birth. Second, we examined relations between FAA and behavioral variables (ASD features, internalizing, and externalizing) within autistic youth, examining effects by sex. Third, we explored whether the relation between FAA, autism features, and mental health was informed by maternal depression history. In our sample, FAA did not differ by diagnosis, age, or sex. However, youth with ASD had lower total frontal alpha power than youth without ASD. For autistic females, FAA and bilateral frontal alpha power correlated with social communication features, but not with internalizing or externalizing symptoms. For autistic males, EEG markers correlated with social communication features, and with externalizing behaviors. Exploratory analyses by sex revealed further associations between youth FAA, behavioral indices, and maternal depression history. In summary, findings suggest that individual differences in FAA may correspond to social-emotional and mental health behaviors, with different patterns of association for females and males with ASD. Longitudinal consideration of individual differences across levels of analysis (e.g., biomarkers, family factors, and environmental influences) will be essential to parsing out models of risk and resilience among autistic youth. En ligne : https://doi.org/10.1002/aur.3032 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=518 [article] Frontal EEG alpha asymmetry in youth with autism: Sex differences and social-emotional correlates [Texte imprimé et/ou numérique] / Megha SANTHOSH, Auteur ; Anna KRESSE, Auteur ; Elizabeth AYLWARD, Auteur ; Raphael BERNIER, Auteur ; Susan BOOKHEIMER, Auteur ; Shafali JESTE, Auteur ; Allison JACK, Auteur ; James C. MCPARTLAND, Auteur ; Adam NAPLES, Auteur ; John D. VAN HORN, Auteur ; Kevin PELPHREY, Auteur ; Sara Jane WEBB, Auteur ; ACE GENDAAR NETWORK, Auteur . - p.2364-2377. in Autism Research > 16-12 (December 2023) . - p.2364-2377 Index. décimale : PER Périodiques Résumé : Abstract In youth broadly, EEG frontal alpha asymmetry (FAA) associates with affective style and vulnerability to psychopathology, with relatively stronger right activity predicting risk for internalizing and externalizing behaviors. In autistic youth, FAA has been related to ASD diagnostic features and to internalizing symptoms. Among our large, rigorously characterized, sex-balanced participant group, we attempted to replicate findings suggestive of altered FAA in youth with an ASD diagnosis, examining group differences and impact of sex assigned at birth. Second, we examined relations between FAA and behavioral variables (ASD features, internalizing, and externalizing) within autistic youth, examining effects by sex. Third, we explored whether the relation between FAA, autism features, and mental health was informed by maternal depression history. In our sample, FAA did not differ by diagnosis, age, or sex. However, youth with ASD had lower total frontal alpha power than youth without ASD. For autistic females, FAA and bilateral frontal alpha power correlated with social communication features, but not with internalizing or externalizing symptoms. For autistic males, EEG markers correlated with social communication features, and with externalizing behaviors. Exploratory analyses by sex revealed further associations between youth FAA, behavioral indices, and maternal depression history. In summary, findings suggest that individual differences in FAA may correspond to social-emotional and mental health behaviors, with different patterns of association for females and males with ASD. Longitudinal consideration of individual differences across levels of analysis (e.g., biomarkers, family factors, and environmental influences) will be essential to parsing out models of risk and resilience among autistic youth. En ligne : https://doi.org/10.1002/aur.3032 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=518

The relationship between gamma-band neural oscillations and language skills in youth with Autism Spectrum Disorder and their first-degree relatives / Vardan ARUTIUNIAN in Molecular Autism, 15 (2024)  

Public ISBD [article]  inMolecular Autism > 15 (2024) . - 19p. Titre : The relationship between gamma-band neural oscillations and language skills in youth with Autism Spectrum Disorder and their first-degree relatives Type de document : Texte imprimé et/ou numérique Auteurs : Vardan ARUTIUNIAN, Auteur ; Megha SANTHOSH, Auteur ; Emily NEUHAUS, Auteur ; Heather BORLAND, Auteur ; Chris TOMPKINS, Auteur ; Raphael A. BERNIER, Auteur ; Susan Y. BOOKHEIMER, Auteur ; Mirella DAPRETTO, Auteur ; Abha R. GUPTA, Auteur ; Allison JACK, Auteur ; Shafali JESTE, Auteur ; James C. MCPARTLAND, Auteur ; Adam NAPLES, Auteur ; John D. VAN HORN, Auteur ; Kevin A. PELPHREY, Auteur ; Sara Jane WEBB, Auteur Article en page(s) : 19p. Langues : Anglais (eng) Mots-clés : Humans  Autism Spectrum Disorder/physiopathology/psychology  Male  Female  Adolescent  Gamma Rhythm  Child  Electroencephalography  Language  Family  Siblings  Autism Spectrum Disorder (ASD)  Excitation/inhibition balance  Gamma power  Language skills  Unaffected siblings  Health, and BlackThorn Therapeutics, has received research funding from Janssen  Research and Development, serves on the Scientific Advisory Boards of Pastorus  and Modern Clinics, and receives royalties from Guilford Press, Lambert, Oxford,  and Springer. The remaining authors have no conflict of interest to declare. Index. décimale : PER Périodiques Résumé : BACKGROUND: Most children with Autism Spectrum Disorder (ASD) have co-occurring language impairments and some of these autism-specific language difficulties are also present in their non-autistic first-degree relatives. One of the possible neural mechanisms associated with variability in language functioning is alterations in cortical gamma-band oscillations, hypothesized to be related to neural excitation and inhibition balance. METHODS: We used a high-density 128-channel electroencephalography (EEG) to register brain response to speech stimuli in a large sex-balanced sample of participants: 125 youth with ASD, 121 typically developing (TD) youth, and 40 unaffected siblings (US) of youth with ASD. Language skills were assessed with Clinical Evaluation of Language Fundamentals. RESULTS: First, during speech processing, we identified significantly elevated gamma power in ASD participants compared to TD controls. Second, across all youth, higher gamma power was associated with lower language skills. Finally, the US group demonstrated an intermediate profile in both language and gamma power, with nonverbal IQ mediating the relationship between gamma power and language skills. LIMITATIONS: We only focused on one of the possible neural contributors to variability in language functioning. Also, the US group consisted of a smaller number of participants in comparison to the ASD or TD groups. Finally, due to the timing issue in EEG system we have provided only non-phase-locked analysis. CONCLUSIONS: Autistic youth showed elevated gamma power, suggesting higher excitation in the brain in response to speech stimuli and elevated gamma power was related to lower language skills. The US group showed an intermediate pattern of gamma activity, suggesting that the broader autism phenotype extends to neural profiles. En ligne : https://dx.doi.org/10.1186/s13229-024-00598-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=538 [article] The relationship between gamma-band neural oscillations and language skills in youth with Autism Spectrum Disorder and their first-degree relatives [Texte imprimé et/ou numérique] / Vardan ARUTIUNIAN, Auteur ; Megha SANTHOSH, Auteur ; Emily NEUHAUS, Auteur ; Heather BORLAND, Auteur ; Chris TOMPKINS, Auteur ; Raphael A. BERNIER, Auteur ; Susan Y. BOOKHEIMER, Auteur ; Mirella DAPRETTO, Auteur ; Abha R. GUPTA, Auteur ; Allison JACK, Auteur ; Shafali JESTE, Auteur ; James C. MCPARTLAND, Auteur ; Adam NAPLES, Auteur ; John D. VAN HORN, Auteur ; Kevin A. PELPHREY, Auteur ; Sara Jane WEBB, Auteur . - 19p. Langues : Anglais (eng) in Molecular Autism > 15 (2024) . - 19p. Mots-clés : Humans  Autism Spectrum Disorder/physiopathology/psychology  Male  Female  Adolescent  Gamma Rhythm  Child  Electroencephalography  Language  Family  Siblings  Autism Spectrum Disorder (ASD)  Excitation/inhibition balance  Gamma power  Language skills  Unaffected siblings  Health, and BlackThorn Therapeutics, has received research funding from Janssen  Research and Development, serves on the Scientific Advisory Boards of Pastorus  and Modern Clinics, and receives royalties from Guilford Press, Lambert, Oxford,  and Springer. The remaining authors have no conflict of interest to declare. Index. décimale : PER Périodiques Résumé : BACKGROUND: Most children with Autism Spectrum Disorder (ASD) have co-occurring language impairments and some of these autism-specific language difficulties are also present in their non-autistic first-degree relatives. One of the possible neural mechanisms associated with variability in language functioning is alterations in cortical gamma-band oscillations, hypothesized to be related to neural excitation and inhibition balance. METHODS: We used a high-density 128-channel electroencephalography (EEG) to register brain response to speech stimuli in a large sex-balanced sample of participants: 125 youth with ASD, 121 typically developing (TD) youth, and 40 unaffected siblings (US) of youth with ASD. Language skills were assessed with Clinical Evaluation of Language Fundamentals. RESULTS: First, during speech processing, we identified significantly elevated gamma power in ASD participants compared to TD controls. Second, across all youth, higher gamma power was associated with lower language skills. Finally, the US group demonstrated an intermediate profile in both language and gamma power, with nonverbal IQ mediating the relationship between gamma power and language skills. LIMITATIONS: We only focused on one of the possible neural contributors to variability in language functioning. Also, the US group consisted of a smaller number of participants in comparison to the ASD or TD groups. Finally, due to the timing issue in EEG system we have provided only non-phase-locked analysis. CONCLUSIONS: Autistic youth showed elevated gamma power, suggesting higher excitation in the brain in response to speech stimuli and elevated gamma power was related to lower language skills. The US group showed an intermediate pattern of gamma activity, suggesting that the broader autism phenotype extends to neural profiles. En ligne : https://dx.doi.org/10.1186/s13229-024-00598-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=538

---

1 (1 - 3 / 3)